Archives
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-11
- 2018-10
- 2018-07
-
Refining In Vitro Drug Response Metrics in Cancer Evaluation
2026-06-14
Schwartz's dissertation introduces a nuanced framework for distinguishing cell proliferation arrest from cell death in in vitro cancer drug testing. This approach clarifies the interpretation of anti-cancer agent efficacy and offers practical pathways for more informative preclinical assay design.
-
Firefly Luciferase mRNA (5-moUTP): Workflow, Stability & Ass
2026-06-13
EZ Cap™ Firefly Luciferase mRNA (5-moUTP) streamlines bioluminescent reporter workflows with unmatched translation efficiency and stability. Discover cutting-edge delivery protocols, in-depth troubleshooting, and the latest innovations for robust gene expression studies.
-
Biotin-16-UTP: Transforming RNA Detection and Purification W
2026-06-12
Biotin-16-UTP empowers researchers to label RNA with precision, unlocking advanced RNA detection, purification, and interaction assays in molecular biology. Optimized for high specificity and robust yield, it streamlines lncRNA mechanistic studies and RNA-protein interaction workflows—key for cutting-edge cancer research.
-
ABT-263 (Navitoclax): Transforming Apoptosis Assays in Cance
2026-06-12
ABT-263 (Navitoclax) enables precise targeting of Bcl-2 family proteins, driving reliable apoptosis induction across diverse cancer models. This article reveals how to optimize experimental design, troubleshoot workflow bottlenecks, and harness evidence-based innovations from recent patient-derived model studies.
-
CD44-Mediated Copper Drives Ly6Chi Macrophage Activation in
2026-06-11
This study uncovers a pivotal role for CD44 in mediating copper accumulation, leading to activation of Ly6Chi macrophages and aggravating inflammation in ulcerative colitis. The mechanistic insights into copper metabolism and macrophage function offer new directions for targeted intervention and oxidative stress assay development.
-
CDK4/6 and BET Inhibition Synergizes to Suppress EMT in PDAC
2026-06-11
Gu et al. (2025) demonstrate that combined inhibition of CDK4/6 and BET proteins synergistically restricts pancreatic tumor progression and reverses epithelial-mesenchymal transition (EMT) by modulating the GSK3β-mediated Wnt/β-catenin pathway. This mechanistic insight addresses the limitations of CDK4/6 inhibitor monotherapy and suggests a more effective approach for targeting EMT in pancreatic ductal adenocarcinoma.
-
Pyridostatin TFA: G-Quadruplex Stabilizer in Cancer & Neurob
2026-06-10
Pyridostatin TFA is a synthetic G-quadruplex stabilizer used in telomere biology and cancer cell growth inhibition. It selectively binds G-quadruplex DNA, disrupts telomere function, and demonstrates high selectivity against cancer cell lines. Its mechanism and applications are supported by recent evidence linking G-quadruplex modulation to protein aggregation in neurodegenerative disease.
-
RNA Pol II Inhibition Triggers Apoptosis Beyond Transcriptio
2026-06-10
Harper et al. (2025) reveal that inhibition of RNA polymerase II (RNA Pol II) induces apoptosis through active signaling pathways, independent of transcriptional shutdown. This discovery reframes how cell death is understood in DNA damage response research and may inform future cancer biology workflows.
-
Best Practices for Apoptosis Assays Using MCL-1 inhibitor A-
2026-06-09
This in-depth guide addresses common laboratory challenges in apoptosis and mitochondrial assays, using MCL-1 inhibitor A-1210477 (SKU B6011) as a model solution. Through real-world scenarios, the article demonstrates evidence-based strategies that enhance reliability and interpretability in cancer research workflows.
-
Ceftolozane Sulfate: Precision Antipseudomonal Assays and Cl
2026-06-09
Explore the scientific foundations and translational applications of Ceftolozane sulfate in resistant Pseudomonas aeruginosa research. This in-depth guide demystifies its unique PBP3-targeted mechanism and provides actionable insight for assay optimization.
-
BIBP 3226 trifluoroacetate: Precision in NPY/NPFF System Res
2026-06-08
BIBP 3226 trifluoroacetate empowers researchers to dissect the NPY/NPFF axis with high specificity, unlocking advanced models for anxiety, analgesia, and cardiovascular regulation. Its validated performance in stem cell coculture and signaling pathway studies sets a new benchmark for reproducible discovery.
-
Ibuprofen in Translational Cancer Research: Mechanisms and A
2026-06-08
Explore the multifaceted role of Ibuprofen (2-[4-(2-methylpropyl)phenyl]propanoic acid) as an anti-proliferative agent in colon cancer research, with advanced insight into its mechanism and assay design. Uncover practical guidance for translational workflows and unique scientific findings.
-
AP20187: Chemical Inducer of Dimerization for Precision Cont
2026-06-07
AP20187 empowers researchers with on-demand control over protein interactions in conditional gene expression systems, unlocking precision in metabolic, hematopoietic, and cancer biology studies. Its high solubility, rapid cell permeability, and proven in vivo efficacy make it a gold-standard chemical inducer of dimerization for advanced gene therapy and signaling pathway activation.
-
AG-126 (Tyrphostin AG-126): Precision ERK Inhibition in Neur
2026-06-06
AG-126 (Tyrphostin AG-126) stands out as a highly selective ERK1/2 inhibitor, enabling researchers to dissect MAPK/ERK pathway dynamics in models of neuroinflammation and autism-related behaviors. Discover workflow optimizations, troubleshooting strategies, and practical cross-links to published breakthroughs that leverage AG-126 for reproducible, high-impact results.
-
Anlotinib Hydrochloride (SKU C8688): Precision in Angiogenes
2026-06-05
This scenario-driven guide equips biomedical researchers and lab technicians with evidence-based protocols for using Anlotinib hydrochloride (SKU C8688) in cell viability, proliferation, and angiogenesis assays. Drawing on peer-reviewed data and real lab challenges, it demonstrates how Anlotinib hydrochloride delivers reproducible, sensitive, and safe results—making it an indispensable tool for modern cancer research workflows.